New England Journal of Medicine · 2019 · 63 citations · 2 references
Public AffairsHealth PolicyHealth Services AdministrationHealth Services ResearchHealthcare FinanceAntiviral TherapyHealthcare PricingUniversal Health CoverageValue-based PaymentViral HepatitisViral Hepatitis TreatmentEssential Medicines EconomicsHepatitis C ManagementInfectious Disease EconomicsMedicine Pricing PolicyUniversal Access To MedicinesValue-based Pricing Impact
Australia’s agreement to spend about 1 billion Australian dollars (U.S.$766 million) over 5 years in exchange for an unlimited volume of hepatitis C drugs suggests that, under certain conditions, innovative approaches to payment can remove price as a barrier to access.
2
Alison L. Hill, Saye Khoo, Joseph Fortunak et al. · Clinical Infectious Diseases · 2014 · 216 citations · Full text